A Study To Estimate The Time Course Of PF-00241939 Concentration In The Blood After Dosing With Oral Inhalation From Dry Powder Inhalers
Phase 1
Completed
- Conditions
- Pharmacokinetics
- Interventions
- Drug: Treatment ADrug: Treatment BDrug: Treatment CDrug: Treatment EDrug: Treatment G
- Registration Number
- NCT01181700
- Lead Sponsor
- Pfizer
- Brief Summary
The purpose of this study is to investigate the time course of PF-00241939 concentrations in the blood following dosing by oral inhalation using dry powder inhalers.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 42
Inclusion Criteria
- Healthy male and/or female subjects between the ages of 21 and 55 years.
- Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).
Exclusion Criteria
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
- Pregnant or nursing females.
- A positive urine drug screen.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Treatment A Treatment A - Treatment B Treatment B - Treatment C Treatment C - Treatment D Treatment D - Treatment E Treatment E - Treatment F Treatment F - Treatment G Treatment G -
- Primary Outcome Measures
Name Time Method Plasma pharmacokinetic parameters: AUClast and Cmax. 36 hours
- Secondary Outcome Measures
Name Time Method Plasma pharmacokinetic parameters: AUC24, AUCinf, Tmax and half-life. 36 hours
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇸🇬Singapore, Singapore